Europe
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here’s who snagged funding this week.
AstraZeneca announced its plans to create a new, separate division for vaccines and antibody therapies, specifically its COVID-19 vaccine developed with the University of Oxford and other COVID-19 antibody treatments.
GlaxoSmithKline is lining up a potential new treatment for patients with anemia due to chronic kidney disease following positive results in a Phase III study.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Researchers with the University of Cambridge in the UK for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
In November 2019, Emory realized this experimental drug could have significant potential in respiratory viruses such as COVID-19.
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
The acquisition of the medicines – which netted AstraZeneca $143 million in the geographies covered under the agreement – provides a significant boost to Covis’s respiratory portfolio.
PRESS RELEASES